Industry News

The Rockefeller University dedicated the $500 million Stavros Niarchos Foundation–David Rockefeller River Campus in May of 2019 in New York. The 160,000-sf complex features the $300 million, 135,600-sf Marie-Josée and Henry R. Kravis Research Building which provides flexible labs, two amphitheaters, offices, conference rooms, a dining area, and outdoor terraces. The two-story, horizontally oriented structure was designed to enhance collaboration and can support over 600 scientific staff.

Chugai Pharmaceuticals will begin construction in August of 2019 on a $1.15 billion research and development center in Yokohama, Japan. Consolidating two labs currently sited in Gotemba and Kamakura, the facility will support drug discovery including the creation of therapies based on next-generation antibodies and synthetic macrocycles, also known as middle molecules. The pharmaceutical research center will leverage leading-edge automation processes and artificial intelligence technologies to accelerate the delivery of innovative medicines to patients worldwide.

Orange Coast College broke ground on the $36 million Kinesiology and Athletics Complex in May of 2019 in Costa Mesa, Calif. Designed by Little Diversified Architectural Consulting, the three-building, 88,000-sf project will house division offices, athletic training and adaptive physical education rooms, student support spaces, locker rooms, a 65-meter competition pool, a 25-meter instructional pool, and a covered 450-person bleacher. General contractor C.W.

Georgia Tech opened the $375 million Coda building in May of 2019. Located at Technology Square in Atlanta, the 755,000-sf innovation hub provides interdisciplinary research space for Georgia Tech's data analytics and computational science programs, as well as offering leasable offices and labs for industry partners. The 21-story tower features a central piazza with a spiral staircase leading to the Collaboration Core, a series of six three-story vertical atriums that join the wings of the building.

WuXi Biologics began construction in May of 2019 on a 1.3 million-sf integrated manufacturing center in Chengdu, China. Meeting the criteria of both the U.S. Food and Drug Administration and the European Medicines Agency's GMP guidelines, the biologics hub will include both drug development and commercial manufacturing facilities. Offering an initial bioreactor capacity of 48,000 liters, the project is WuXi's twelfth drug substance manufacturing plant and will use the company's open-access and proprietary platforms.